As insurers phase out pandemic-related flexibilities, many are raising new obstacles to try to limit their financial exposure.

Subcategories:Clinical Criteria/GuidelinesEthicsLegal UpdatesLegislation & AdvocacyMeeting ReportsResearch Rheum
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!
Larry Beresford |
As insurers phase out pandemic-related flexibilities, many are raising new obstacles to try to limit their financial exposure.
On Aug. 1, UnitedHealthcare implemented a new policy on Services Incident-to a Supervising Health Care Provider that allows for appropriate reimbursement for “incident-to” services consistent with current Medicare guidelines.
With lawmakers home for the summer recess, you have the opportunity to meet with them in their local offices and help them understand how key legislation affects patients and healthcare providers. The ACR offers tools, resources and more to help.
Brenda Lee Frie, EdD, OTR/L, CHT, uses her experiences in professional advocacy to inspire her students to get involved and make a difference from the earliest stages of their careers.
In a small study, patients with GCA maintained remission after receiving three days of treatment with methylprednisolone followed by tocilizumab.
In a study, Janus kinase inhibitors proved effective for patients with difficult-to-treat rheumatoid arthritis (RA).
Lee et al. examined the use of a smartphone application to monitor longitudinal electronic patient-reported outcomes on satisfaction and disease activity in patients with RA.
Applications are now open for the ACR’s Advocacy 101 program, held in conjunction with Advocates for Arthritis. Amanda Schnell, MD, describes how ACR/ARP members can learn to be successful advocates for rheumatology.
On July 9, U.S. President Joe Biden issued an Executive Order designed to promote competition in the U.S. economy. The order includes 72 initiatives related to various aspects of the economy, including prescription drugs and health insurance.1 For prescription drugs, Americans pay more than 2.5 times as much for the same prescription drugs as patients…
Weighing treatment options and adjusting them to meet the needs of patients with JIA is a complicated process. Experts discussed factors influencing treatment options, optimizing treatment doses and possibilities for treatment withdrawal for these patients.